Paramyxoviridae

Nirsevimab demonstrated protection against respiratory syncytial virus disease in healthy infants in Phase 3 trial

Retrieved on: 
Monday, April 26, 2021

No clinically meaningful differences in safety results between the nirsevimab and placebo groups were seen.

Key Points: 
  • No clinically meaningful differences in safety results between the nirsevimab and placebo groups were seen.
  • \xe2\x80\x9cIn fact, most hospitalizations occur in otherwise healthy infants born at term.
  • It\xe2\x80\x99s clear all infants need protection from RSV, and we hope nirsevimab becomes an important addition to routine immunization schedules.\xe2\x80\x9d\n\xe2\x80\x9cThese ground-breaking results mark a major scientific advancement in our effort to provide protection against respiratory syncytial virus for all infants.
  • Nearly all children will contract the virus before age two, leading to nearly 30 million acute lower respiratory tract infections globally each year,\xe2\x80\x9d said Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca.

ReViral and LianBio Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Sisunatovir in China

Retrieved on: 
Tuesday, March 2, 2021

In addition, ReViral is eligible to receive tiered low double-digit royalties on sisunatovir net sales in the licensed territories.

Key Points: 
  • In addition, ReViral is eligible to receive tiered low double-digit royalties on sisunatovir net sales in the licensed territories.
  • LianBio will be responsible for the development and commercialization of sisunatovir in the licensed territories, and ReViral will continue to be responsible for the development and commercialization of sisunatovir in all other geographies.
  • We are delighted to be entering into this collaboration with LianBio to advance sisunatovir in China, a market with a significant unmet medical need for patients with serious RSV infection, said Alex Sapir, CEO, ReViral.
  • The compelling clinical data ReViral has generated to date suggest sisunatovir has the potential to be a highly effective treatment option for RSV.

Codagenix Secures U.S. Patent for Codon-Deoptimized RSV Vaccine Candidates

Retrieved on: 
Tuesday, January 26, 2021

NEW YORK, Jan. 26, 2021 /PRNewswire/ -- Codagenix Inc. , a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies, today announced the issuance of a patent for a vaccine focused on human codon-deoptimized respiratory syncytial viruses (RSV) vaccine.

Key Points: 
  • NEW YORK, Jan. 26, 2021 /PRNewswire/ -- Codagenix Inc. , a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies, today announced the issuance of a patent for a vaccine focused on human codon-deoptimized respiratory syncytial viruses (RSV) vaccine.
  • 10,695,414 broadens Codagenix's intellectual property portfolio, covering human codon deoptimization of the RSV F and/or G proteins of in a live-attenauted vaccine.
  • Codagenix is currently investigating its live attenuated CodaVax-RSV vaccine, an intranasally-administered vaccine for the prevention of RSV, in a randomized, double-blind, placebo-controlled Phase 1 clinical trial.
  • Codagenix's RSV vaccine has shown excellent safety and efficacy in non-human primate models, eliciting both antibody and cellular-based immune responses and protecting against RSV infection.

Meissa Announces First Dosing in Phase 2 Study of Intranasal Live Attenuated Vaccine Candidate for RSV

Retrieved on: 
Thursday, January 21, 2021

Meissa Vaccines (Meissa), a biotechnology company developing vaccines to prevent viral respiratory infections, announced today that the first adult participants have been dosed in a Phase 2 study of MV-012-968, the companys intranasal live attenuated vaccine candidate against respiratory syncytial virus (RSV).

Key Points: 
  • Meissa Vaccines (Meissa), a biotechnology company developing vaccines to prevent viral respiratory infections, announced today that the first adult participants have been dosed in a Phase 2 study of MV-012-968, the companys intranasal live attenuated vaccine candidate against respiratory syncytial virus (RSV).
  • Meissa is developing MV-012-968, an intranasal (needle-free), live attenuated vaccine candidate, to protect infants and at-risk, older adults from RSV.
  • Meissa plans to initiate a Phase 1c study in sero-negative infants in the first half of this year.
  • Meissa is advancing live attenuated vaccine candidates against life threatening respiratory viruses, including respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19), and human metapneumovirus (hMPV).

MediciNova Announces Initiation of Master Virus Seed Stock Production for its Intranasal COVID-19 Vaccine using BC-PIV Vector Technology

Retrieved on: 
Tuesday, November 24, 2020

We look forward to producing an effective intranasal COVID-19 vaccine and reporting additional development progress in the near future.

Key Points: 
  • We look forward to producing an effective intranasal COVID-19 vaccine and reporting additional development progress in the near future.
  • BC-PIV, an innovative non-transmissible viral vector co-developed by BioComo and Mie University, is derived from the recombinant human parainfluenza virus type 2 (hPIV2).
  • To date, BioComo has succeeded in producing a recombinant Ebola virus vaccine ( https://www.nature.com/articles/s41598-019-49579-y ) and a Respiratory Syncytial virus prefusion F vaccine (unpublished data) using this BC-PIV platform technology.
  • Their technology will be applied to the production of the next generation vaccines for the prevention of infections such as RS virus, Ebola virus, Influenza virus, and SARS-CoV-2.

COVID-19 Impacts: Respiratory Syncytial Virus Diagnostics Market Will Accelerate at a CAGR of Almost 10% Through 2020-2024 | Increase in Product Launches to Boost Growth | Technavio

Retrieved on: 
Wednesday, November 4, 2020

The respiratory syncytial virus diagnostics market is poised to grow by USD 585.17 million during 2020-2024 progressing at a CAGR of almost 10% during the forecast period.

Key Points: 
  • The respiratory syncytial virus diagnostics market is poised to grow by USD 585.17 million during 2020-2024 progressing at a CAGR of almost 10% during the forecast period.
  • Download Free Sample Report on COVID-19 Recovery Analysis
    The report on the respiratory syncytial virus diagnostics market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.
  • The respiratory syncytial virus diagnostics market analysis includes product segment and geography landscape.
  • This study identifies the technological advancements as one of the prime reasons driving the respiratory syncytial virus diagnostics market growth during the next few years.

Tonix Pharmaceuticals to Participate in Upcoming September Virtual Investor Conferences

Retrieved on: 
Thursday, August 27, 2020

The immunology portfolio includes vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer and autoimmune diseases.

Key Points: 
  • The immunology portfolio includes vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer and autoimmune diseases.
  • The CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions.
  • Tonix expects data from animal studies of TNX-1800 in the fourth quarter of this year.
  • Tonix is also developing TNX-2300*, a second live replicating vaccine candidate for the prevention of COVID-19, but using bovine parainfluenza as the vector.

Respiratory Syncytial Virus Infections - Pipeline Review, H1 2020 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 19, 2020

The "Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This report provides an overview of the Respiratory Syncytial Virus Infections (Infectious Disease) pipeline landscape.
  • The Respiratory Syncytial Virus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Respiratory Syncytial Virus (RSV) Infections and features dormant and discontinued projects.
  • Formulate corrective measures for pipeline projects by understanding Respiratory Syncytial Virus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

ReViral Announces FDA Fast Track Designation Granted to Sisunatovir For The Treatment of Serious Respiratory Syncytial Virus Infection

Retrieved on: 
Tuesday, August 4, 2020

ReViral Ltd., a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics that target respiratory syncytial virus (RSV), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to sisunatovir for the treatment of patients with serious RSV infection.

Key Points: 
  • ReViral Ltd., a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics that target respiratory syncytial virus (RSV), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to sisunatovir for the treatment of patients with serious RSV infection.
  • We are very pleased that sisunatovir has received Fast Track designation for the treatment of serious RSV, a significant global health concern, said Alex Sapir, CEO, ReViral.
  • A drug candidate with Fast Track designation is eligible for greater access to the FDA for the purpose of expediting the drug product candidate's development, review, and potential approval.
  • ReViral is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics, with an initial focus on the treatment of respiratory syncytial virus (RSV).

Nirsevimab reduced respiratory syncytial virus infections requiring medical care in healthy premature infants in Phase 2b trial

Retrieved on: 
Thursday, July 30, 2020

ET

Key Points: 
  • ET
    PARIS July 30, 2020 Detailed results from the positive Phase 2b trial for nirsevimab showed a significant reduction in medically attended lower respiratory tract infections (LRTI), mainly bronchiolitis and pneumonia, and hospitalizations caused by respiratory syncytial virus (RSV) in healthy preterm infants.
  • Nirsevimab offers the important potential to reduce hospitalizations and emergency department and in-office visits, which are a significant burden for healthcare systems.
  • Healthy preterm infants of 2935 weeks gestation were randomized (2:1) to receive a single intramuscular injection of nirsevimab or placebo.
  • With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.